Multiple Sclerosis: Where Will We Be in 2020?

被引：18
|
作者：
Miller, Aaron E. [1 ]
机构：
[1] Mt Sinai Sch Med, New York, NY USA
来源：
MOUNT SINAI JOURNAL OF MEDICINE | 2011年 / 78卷 / 02期
关键词：
genetics; immunology; MS; multiple sclerosis; therapeutics; PLACEBO-CONTROLLED TRIAL; EPSTEIN-BARR-VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DOUBLE-BLIND; ORAL FINGOLIMOD; MULTICENTER; RISK; DISABILITY; INTERFERON-BETA-1A; NATALIZUMAB;
D O I：
10.1002/msj.20242
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The past decade has seen a surge of research interest in multiple sclerosis and an accelerated expansion of investigative efforts into multiple sclerosis therapeutics. Investigators have continued dissecting the complex immunological perturbations that may contribute to the disease and made major advances in understanding the genetics of multiple sclerosis. This article addresses current investigative issues and offers predictions about where the understanding and treatment of multiple sclerosis may stand at the end of the 21st century's second decade. Mt Sinai J Med 78:268-279, 2011. (C) 2011 Mount Sinai School of Medicine
引用
收藏
页码：268 / 279
页数：12
相关论文
共 50 条
  • [1] Pediatric Multiple Sclerosis: What we know and where are we headed?
    MacAllister, William S.
    Christodoulou, Christopher
    Milazzo, Maria
    Preston, Thomas E.
    Serafin, Dana
    Krupp, Lauren B.
    Harder, Lana
    CHILD NEUROPSYCHOLOGY, 2013, 19 (01) : 1 - 22
  • [2] Cellular therapy in multiple sclerosis: where we are and where we are going
    G. Martino
    Neurological Sciences, 2005, 26 : s21 - s21
  • [3] Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?
    Moura, Rui Pedro
    Sarmento, Bruno
    ADVANCED THERAPEUTICS, 2019, 2 (10)
  • [4] Multiple sclerosis: current treatment algorithms
    Rio, Jordi
    Comabella, Manuel
    Montalban, Xavier
    CURRENT OPINION IN NEUROLOGY, 2011, 24 (03) : 230 - 237
  • [5] Cellular therapy in multiple sclerosis: where we are and where we are going
    Martino, G
    NEUROLOGICAL SCIENCES, 2005, 26 (Suppl 1) : S21 - S21
  • [6] Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
    Bosma, L. V. A. E.
    Kragt, J. J.
    Brieva, L.
    Khaleeli, Z.
    Montalban, X.
    Polman, C. H.
    Thompson, A. J.
    Tintore, M.
    Uitdehaag, B. M. J.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (07) : 862 - 867
  • [7] Vitamin D and multiple sclerosis: where do we go from here?
    Salzer, Jonatan
    Bistrom, Martin
    Sundstrom, Peter
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (01) : 9 - 18
  • [8] An update on combination therapies for multiple sclerosis: where are we now?
    Sorensen, Per Soelberg
    Magyari, Melinda
    Sellebjerg, Finn
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (12) : 1173 - 1187
  • [9] Multiple sclerosis in Kashmir: Where we stand
    Zahoor, Insha
    Haq, Ehtishamul
    Asimi, Ravouf
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 373 : 129 - 133
  • [10] Current Disease-Modifying Treatment of Multiple Sclerosis
    Derwenskus, Joy
    MOUNT SINAI JOURNAL OF MEDICINE, 2011, 78 (02): : 161 - 175
12345